129 related articles for article (PubMed ID: 2786104)
1. [Regional transarterial infusion of autologous lymphokine-activated killer (LAK) cells for advanced renal cell carcinoma and its preliminary clinical result].
Hayakawa M; Masuda T; Higa I; Koyama Y; Hatano T; Oda M; Osawa A
Nihon Hinyokika Gakkai Zasshi; 1989 Jan; 80(1):28-34. PubMed ID: 2786104
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2.
Hayakawa M; Hatano T; Ogawa Y; Gakiya M; Ogura H; Osawa A
Urol Int; 1994; 53(3):117-24. PubMed ID: 7645136
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
5. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer traffic assay and our preliminary clinical results of regional arterial infusion of lymphokine-activated killer cells for renal cell carcinoma.
Hayakawa M; Koyama Y; Williams RD; Osawa A
Urol Int; 1991; 47 Suppl 1():127-31. PubMed ID: 1949369
[TBL] [Abstract][Full Text] [Related]
7. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
8. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
Nakano E
Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
10. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
Hayakawa M
Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Merchant RE; Grant AJ; Merchant LH; Young HF
Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
[TBL] [Abstract][Full Text] [Related]
14. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
[TBL] [Abstract][Full Text] [Related]
15. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
16. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
Gambacorti-Passerini C; Hank JA; Albertini MR; Borchert AA; Moore KH; Schiller JH; Bechhofer R; Borden EC; Storer B; Sondel PM
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):43-8. PubMed ID: 8435431
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
19. [Bronchial arterial infusion of lymphokine-activated killer cells stimulated by autologous tumor cells].
Kimura H; Yamaguchi Y; Obata S; Yusa T; Sekine Y
Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2401-4. PubMed ID: 3137876
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA
Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]